Canada’s Drug Agency has published a new position statement on the use of artificial intelligence (AI) methods in health technology assessment (HTA).
The work of Canada’s Drug Agency is grounded in the independent assessment and evaluation of evidence, which is provided to health system leaders…
Enhancing how we involve patient organizations and people with lived experience in our work is a key ambition at Canada’s Drug Agency. As part of our continuous improvement efforts, we are launching a new initiative that aims to evolve our approach to incorporating the patient voice in our drug…
Now Recruiting Patient Partners for our Rare Disease Registry Request for Proposals Evaluation Panel
In March 2025, Canada’s Drug Agency launched a funding opportunity for rare disease registries to enhance their capability and implement improvement initiatives to support decision-making in Canada related to drugs for rare diseases. Through a Request for Proposals (RFP), this time-limited funding…
Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030.
This is our first strategic plan as Canada’s Drug Agency and we used the opportunity to define who we are, what we do, and how we can provide ever-improving value for decision-makers, patients, and health…
Canada’s Drug Agency has published new guidance to support newborn screening programs in Canada, which play an important role in the early diagnosis of serious conditions and rare diseases.
This guidance was developed by the Newborn Screening Advisory Panel to support the National Strategy for…
Canada’s Drug Agency has launched a new funding opportunity for rare disease registries to enhance their capability and implement improvement initiatives, to support decision-making in Canada related to drugs for rare diseases. This marks our second funding opportunity for rare disease registries,…
New Watch List Spotlights Advances and Issues in Artificial Intelligence Use in Canadian Health Care
The use of artificial intelligence (AI) has the potential to reshape many aspects of the health care systems in Canada, from streamlining documentation and workflows to improving how conditions are diagnosed and tailoring treatments plans.
The 2025 Watch List, published by Canada’s Drug Agency,…
The US-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have selected the first research topic for the Health Economics Methods Advisory (HEMA) group: an assessment of the benefits of…
Today, for the 2nd year running Canada’s Drug Agency was named one of the National Capital Region's top employers for 2025.
This special designation recognizes employers in the Ottawa-Gatineau metropolitan area that lead their industries in offering exceptional places to work. Canada’s Drug Agency…
Canada’s Drug Agency is seeking knowledgeable and experienced individuals to join our expert and advisory committees.
Our annual call for nominations is now open for the following positions:
1 patient member on the Canadian Drug Expert Committee (CDEC)
1 expert member on the pan-Canadian Oncology…
On Rare Disease Day — a global event dedicated to raising awareness for the millions of people living with rare diseases — Canada’s Drug Agency has published new pan-Canadian guidance on best practices and standards for rare disease registries (RDRs). The guidance, aligned with international…
Leaders of 3 health technology assessment organizations convene working group and steering committee to critically and independently research new health economic methods
The USA-based Institute for Clinical and Economic Review (ICER), England’s National Institute for Health and Care Excellence (…